Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.05.06.21256768: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The Institutional Review Board at Stanford University reviewed and approved the study. Sex as a biological variable not detected. Randomization From among the 17,390 seronegative patients in January 2021, we used systematic sampling with fraction intervals stratified by age to randomly select 4,346 persons to follow with monthly SARS-CoV-2 serology assays, in association with type and date of vaccination(s) (Figure 1). Blinding not detected. Power Analysis not detected. Cell Line Authentication Authentication: This assay is reported by the manufacture to have 100% sensitivity and 99.8% specificity for tests performed ≥14 days after a positive reverse transcriptase polymerase chain reaction … SciScore for 10.1101/2021.05.06.21256768: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The Institutional Review Board at Stanford University reviewed and approved the study. Sex as a biological variable not detected. Randomization From among the 17,390 seronegative patients in January 2021, we used systematic sampling with fraction intervals stratified by age to randomly select 4,346 persons to follow with monthly SARS-CoV-2 serology assays, in association with type and date of vaccination(s) (Figure 1). Blinding not detected. Power Analysis not detected. Cell Line Authentication Authentication: This assay is reported by the manufacture to have 100% sensitivity and 99.8% specificity for tests performed ≥14 days after a positive reverse transcriptase polymerase chain reaction test17; it has been validated independently with similar performance characteristics18,19. Table 2: Resources
Antibodies Sentences Resources Ascend Clinical tested remainder plasma of patients for SARS-CoV-2 antibody, and anonymized all patient demographic, comorbidity, and laboratory data prior to transfer to Stanford University. SARS-CoV-2suggested: NoneAssay Characteristics: We tested remainder samples using the Siemens’ total RBD Ig assay, which measures IgG and IgM antibodies, in January 2021 and monthly thereafter in the seronegative prior to vaccination cohort. IgMsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of the study include the modest sample size. Our assessment was performed during the early phase of vaccine roll out, a time period during which elderly or persons with comorbidities were prioritized. Estimates for vaccine response may improve over time as a broader patient population receives vaccination, although 40% of our cohort was < 65 years of age indicating reasonable representativeness by age of patients receiving dialysis. Antibody titers are only one way to assess immunologic response to vaccination. We do not yet know whether the strength or duration of a measurable antibody response correlates with protection from infection. In summary, in a well-characterized cohort of patients receiving dialysis with and without prior evidence of infection with SARS-CoV-2, more than one in five demonstrated an attenuated immune response after vaccination with one of three vaccines granted emergency use authorization by FDA. These findings may inform subsequent vaccination strategies in the ESKD population and in other persons with chronic illness.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
